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INTRODUCTION
TP53 variant carriers have a lifetime risk of developing cancer of about
75% in males and almost 100% in females. There is no prevention or
treatment for Li-Fraumeni syndrome, so screening is important to ensure
that cancer is detected early. Most of these individuals will develop
common cancers associated with the condition while others will have or
be at risk for developing other types of cancer. Rare TP53 germline
variations are the key to understanding and discovering the incongruities
of cancer predisposition in these individuals. This study conducted a
focused assessment of rare TP53 variants through a whole-exome casecontrol study to determine how likely each cancer was to occur in
individuals with the same variants and the certainty of association
between variants and cancer predisposition.

METHOD
•

DNA from a total of 13,396 cases and 1,391 to 3,801 controls from
the University of Texas MD Anderson Cancer Center (MDA), H. Lee
Moffitt Cancer Center & Research Institute, The University of Utah
School of Medicine, Duke University, and UK Biobank.

•

Whole-exome sequencing was performed using Agilent SureSelect
Clinical Research Exome v1/v2 and Illumina HiSeq 4000/NovaSeq
6000 to an average depth of 120-150x.

•

We calculated gene-based p-values to test for associations with rare
(minor allele frequency [MAF] < 0.005) TP53 protein-coding variation
and each cancer using VAAST. Odds ratios(OR) and Confidence
intervals for each variant category were then determined for each
type of cancer.

•

Meta-analysis was conducted using the published case/control counts
for each study. A simple logistic regression was used to estimate the
odds ratio and standard error for each study. The odds were
combined using a fixed effects model.

Rare TP53 Variants can predispose individuals to
multiple cancers that are not Commonly
Associated with Li-Fraumeni Syndrome

RESULTS
We report gene-based association results for rare protein-coding variants
in TP53 for each of the five cancer types. We also report OR point
estimates and confidence intervals for pathogenic, VUS, and benign
variants in each cancer. For pathogenic variants, we conducted a metaanalysis incorporating 1-2 additional studies for each cancer type.

DISCUSSION
Our results provide evidence that rare TP53 protein-coding variants
confer an increased risk of colorectal, melanoma, ovarian, pancreatic,
and prostate cancer, in part due to missense variation which is not
currently classified as pathogenic. Our meta-analysis results provide
precise estimates of the risk conferred by pathogenic TP53 variants for
each cancer type. Future studies will expand this analysis to other
cohorts and integrate this dataset with additional controls from other
sources, such as UK Biobank, to improve risk estimate precision.
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